Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)Pei‐Pei Kung, Martin P. Edwards, Lisa Nguyen et al.|Journal of Medicinal Chemistry|2017Cited by 129
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2 <i>H</i> )-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei‐Pei Kung, Martin P. Edwards, Eugene Rui et al.|Journal of Medicinal Chemistry|2016Cited by 70
Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor AntagonistsChuangxing Guo, Andrea Fanjul, Angelica Linton et al.|Journal of Medicinal Chemistry|2011Cited by 69
Use of the dTAG system <i>in vivo</i> to degrade CDK2 and CDK5 in adult mice and explore potential safety liabilitiesPaul Yenerall, Wenyue Hu|Toxicological Sciences|2023Cited by 15
Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.Ted W. Johnson, Helen Y. Zou, Simon Bailey et al.|Molecular Cancer Therapeutics|2013Cited by 4